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Abstract
Expression proﬁling of target genes in patient blood is a powerful tool for RNA diagnosis. Here, we
describe GenopalTM, a novel platform ideal for efﬁcient focused microarray analysis. GenopalTM, which
consists of gel-ﬁlled ﬁbres, is advantageous for high-quality mass production via large-scale slicing of
the GenopalTM block. We prepared two arrays, infectant and autoimmunity, that provided highly reliable
data in terms of repetitive scanning of the same and/or distinct microarrays. Moreover, we demonstrated
that GenopalTM had sensitivity sufﬁcient to yield signals in short hybridization times (0.5 h). Application
of the autoimmunity array to blood samples allowed us to identify an expression pattern speciﬁc to
Takayasu arteritis based on the Spearman rank correlation by comparing the reference proﬁle with
those of several autoimmune diseases and healthy volunteers (HVs). The comparison of these data with
those obtained by other methods revealed that they exhibited similar expression proﬁles of many
target genes. Taken together, these data demonstrate that GenopalTM is an advantageous platform for
focused microarrays with regard to its low cost, rapid results and reliable quality.
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1. Introduction
Genome-wide expression proﬁling based on micro-
array technology is a powerful tool for both basic and
clinical research focused on understanding genetic
interactions and changes in gene pathways. It also
facilitates the identiﬁcation of genomic biomarkers
that correlate with disease classiﬁcation and with
patient responses to drug treatment. For practical
diagnostic purposes, however, the currently available
general-purpose microarrays have signiﬁcant draw-
backs. Large volumes of data, such as from 40 000
genes or more, are not feasibly managed or analysed.
Moreover, the high cost of the microarrays and the
compound scanning tools has also hampered the
clinical application of microarray systems. In contrast,
customized, focused microarrays are advantageous for
clinical use because they harbour a substantial, but
not overwhelming, number of speciﬁc genes that
allow researchers and clinicians to evaluate the state
of target cells in a relatively inexpensive, rapid, and
reliable way.
1 Focused microarrays have been success-
fully applied to the analysis of human embryonic stem
cell differentiation,
2 dopaminergic and glial cell differ-
entiation,
3 transcriptional regulation of the glycome,
4
glyco gene targets with therapeutic potential,
5 gene
expression in the mitochondria,
6 oestrogenic activity
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7 and the cell state of non-small cell
lung cancer patients.
8 Unfortunately, the focused
microarrays currently available, which are based on
the two-dimensional display of oligonucleotides on a
glass-based platform, do not offer a substantial econ-
omic advantage, reliable quality or the possibility for
large-scale production.
We report here the development and practical
application of a novel platform for focused microarray,
termed GenopalTM. The performance of two types of
focused microarrays were validated using ﬂuores-
cently labelled antisense oligonucleotides selected
from the genomes of infectious bacteria and viruses
for the former, and complementary RNAs (cRNAs)
derived from peripheral blood mononuclear cells
(PBMCs) of Takayasu arteritis (TA) patients for the
latter. TA is a rare autoimmune disease of unknown
origin that predominantly affects women and leads
to inﬂammation of the large arteries, resulting in
various types of aortoarterial stenosis/occlusion or
dilatation.
9,10. Here, microarray analysis based on
the Spearman rank correlation identiﬁed an
expression pattern speciﬁc to TA, which suggests that
the GenopalTM is useful for the diagnosis of TA.
2. Patients, Materials and Methods
2.1. Human subjects and ethical considerations
All systemic vasculitis patients used in this study
were diagnosed according to a previously documen-
ted proposal (the ACR criteria and the CHCC criteria).
This study was reviewed and approved by the Internal
Review Board of the Research Institute for Microbial
Diseases, Osaka University. Accordingly, written
informed consent was obtained from all participants
before their PBMCs were obtained. Serum samples
were consecutively obtained regardless of the
patient’s symptom, active or inactive phase.
2.2. Production of hollow ﬁbre arrays
GenopalTM consists of hollow ﬁbres impregnated
with gel that ﬁrmly adheres to the inner walls of the
ﬁbres via the introduction of comb polymers
(Fig. 1A). Detailed technical aspects of GenopalTM
are described in the following patents: US7122378,
US20040234114, US20040258897, US2005006
3877 and EP1627839. Brieﬂy, methyl methacrylate
(MMA, 100 parts), glycidyl methacrylate (GMA, 100
parts) and azobisisobutyronitrile (AIBN, 0.5 parts)
were added dropwise to methyl ethyl ketone (MEK,
50 parts) at 808C in a nitrogen gas stream (50 ml/
min) for 3 h. AIBN (0.1 parts) and MEK (70 parts)
were then added, and the mixture was allowed to
stand for 1 h. Subsequently, AIBN (0.1 parts) and
MEK (10 parts) were added, and the resulting
product was allowed to stand for 3 h before the
addition of MEK (50 parts). Thereafter, methylhydro-
quinone (0.5 parts), triphenylphosphine (2.5 parts)
and acrylic acid (99 mol % GMA) were added.
During these procedures, reactions were aerated
(100 ml/min) and allowed to proceed for 30 h.
Comb polymers with vinyl groups added to their
side-chain termini were obtained. These copolymers
contained 25 mol % vinyl groups (Fig. 1B).
Two hundred and twenty-ﬁve hollow poly-MMA
ﬁbres (outer diameter, 300 mm; inner diameter,
Figure 1. Structure of GenopalTM and its mass production
application via slicing of the GenopalTM block. (A) Schematic
representation of the GenopalTM microarray, which is
composed of plastic hollow ﬁbres. Oligonucleotide DNA
capture probes were attached to a hydrophilic gel within the
three-dimensional space of each hollow ﬁbre. (B) The chemical
structure of the comb polymers containing polymer-forming
functional groups on their side chains. These polymers were
inserted into the hollow ﬁbres. (C) Comb polymers with poly
HEMA added to their side chains ﬁrmly adhered to the inner
walls of the hollow ﬁbres. (D) Schematic representation of a
GenopalTM block: the hollow ﬁbres were bundled in an orderly
arrangement, hardened with resin to form a GenopalTM block
and sliced into thin microarrays.
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Tokyo, Japan) were bundled, and comb polymers
were introduced into the hollow portions. Part of
the solution introduced by suction into the hollow
portions was transferred to the trap tube, and the
solvent remaining on the inner walls of the hollow
portions was allowed to evaporate by air drying.
Subsequently, two porous plates (thickness, 0.1 mm)
comprising 49 pores each arranged in seven rows in
both lengthwise and breadthwise directions, with a
pore diameter of 0.32 mm and centre-to-centre dis-
tances between neighbouring pores of 0.42 mm,
were stacked. Forty-nine hollow ﬁbres of poly-MMA
were allowed to pass through each pore of these
two porous plates. The distance between the two
porous plates was 50 mm, and both ends were
immobilized while the threads were stretched
between them. The starting material for the resin
was then made to ﬂow into the hollow ﬁbre array
and allowed to harden. Polyurethane resin adhesives
(Nippolan 4276, Coronate 4403; by Nihon
Polyurethane Industry Co. Ltd, Shunan-shi, Japan)
were used. The porous plates were removed after
the resin hardened, producing the resin block con-
taining hollow ﬁbres.
In the ﬁnal step of the oligonucleotide synthesis, the
reaction was performed using Aminolink II (Applied
Biosystems, Foster City, CA, USA) to synthesize an oli-
gonucleotide with aminated termini. The resulting
GCAT oligo with aminated termini (50 ml,
500 nmol/ml), GMA (5 ml) and dimethylformamide
(5 ml) were mixed, and the mixture was allowed to
react at 708C for 2 h before the addition of 190 ml
of water. Thus, we obtained a GCAT oligo with
100 nmol/ml methacrylate groups (MA-GCAT).
Subsequently, we prepared a starting solution for a
gel comprise the monomer and the initiator with
the following mass ratios: 9 parts acrylamide, 1 part
N,N0-methylenebisacrylamide, 0.1 part 2,20-azobis
(2-methylpropionamidine)dihydrochloride (V-50)
and 90 parts water. MA-GCAT was then added to
the above solution to a ﬁnal concentration of
0.5 nmol/l. The hollow portions of the hollow ﬁbres
in the resin block were ﬁlled with this solution, the
block was transferred into a humidiﬁed hermetically
sealed glass vessel, and the content of the vessel was
allowed to polymerize at 708C for 3 h. Thus, a block
of hollow ﬁbre array in which the hollow portion
was impregnated with gel was obtained. This block
was sliced to a thickness of 500 mm in a direction per-
pendicular to the direction of ﬁbres.
2.3. Preparation of infectant and autoimmunity arrays
The infectant GenopalTM probe (iGp) array were
comprise 60 nucleotides (nts) from the genome
sequences of 40 types of infectious bacteria and
viruses (Supplementary Table S1), taking into con-
sideration the speciﬁcity, melting temperature, GC
content (40–60%) and secondary structure predicted
with ProbeQuest software (Dynacom Co., Chiba,
Japan). The generated synthetic DNA oligonucleotides
were installed onto a GenopalTM platform to keep
them immobilized in the hydrophilic gel within the
three-dimensional space of each hollow ﬁbre
(Mitsubishi Rayon Co. Ltd). To prepare autoimmunity
GenopalTM probe (aGp) array, 216 genes were
selected based on their relevance to autoimmune dis-
eases (Supplementary Fig. S2A and Table S2), 65 nt
GenopalTM probes with similar annealing tempera-
tures were designed, and the oligonucleotides were
synthesized and installed onto the GenopalTM plat-
form. Here, we also considered the melting tempera-
ture, GC content, speciﬁcity, secondary structure and
low complexity of the sequences, which were primar-
ily located within 1000 bases of the 30 end of mRNA
sequences.
2.4. RNA isolation
Total RNA from fresh PBMCs of patients and pooled
healthy volunteers (HV pools) was isolated using the
PAXgene Blood RNA Kit and RNeasy Mini Kit with
the optimal on-column DNase digestion, according
to the manufacturer’s instructions (Qiagen KK,
Hilden, Germany). The quality of the RNA samples
used for the microarray analysis was examined using
the RNA 6000 Nano LabChip Kit (p/n 5067-1511)
on the Agilent 2100 Bioanalyzer (G2938C; Agilent
Technologies Inc., Palo Alto, CA, USA).
2.5. Microarray analysis on GenopalTM
Hybridizations on the infectant and autoimmunity
arrays were carried out in 150 ml of hybridization
buffer (0.12 M Tris–HCl, pH 7.5, 0.12 M NaCl,
0.05% Tween-20 and the indicated amount of anti-
sense-oligonucleotides or 1125 ng of cRNA) at 658C
overnight or for the indicated times (for time-course
measurements; Supplementary Fig. S1B) in a
GenopalTM-speciﬁc hybridization chamber
(Mitsubishi Rayon Co. Ltd). After hybridization, the
GenopalTM arrays were washed twice in 0.12 M
Tris–HCl (pH 7.5), 0.12 M NaCl and 0.05% Tween-
20 at 658C for 20 min, followed by washing in
0.12 M Tris–HCl (pH 7.5), 0.12 M NaCl at room
temperature for 10 min. The GenopalTM array was
then scanned, and the image was captured using a
cooled charge-coupled device type Microarray Image
Analyzer equipped with multibeam excitation tech-
nology (Yokogawa Electric Co., Tokyo, Japan). For
infectant array data, Microsoft Excel was used to cal-
culate the coefﬁcient of variation (CV) between
No. 6] D. Okuzaki et al. 371arrays, between scans and between sections. For auto-
immunity array data, signal intensities were processed
by Subio Basic Plug-in (v1.6; Subio Inc., Aichi, Japan) as
follows. First, all values ,1 were replaced by 1 and
log2 transformed. Next, ratios against intensities of
the HV pools were calculated. Processed signals from
13 TA samples were averaged by 216 genes to gener-
ate a reference TA proﬁle. Finally, the Spearman rank
correlation between each sample and the reference
TA proﬁle by R were calculated. The details of the
microarray data have been deposited in the Gene
Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/
geo) database (accession number GSE18247).
2.6. Data analysis of aGp array
We obtained raw data by measuring the signal
intensity with exposure time of 0.1, 1.0, 4.0, 40 and
120 s. Then, we calculated the values of average,
median and standard deviation (SD) for 216 probe
and 12 blank wells (background). In most cases, the
subtracted value (median value of 216 probes
minus median value of background) exceeded the
SD value of background. Thus, we employed it as the
expression value. If not, we employed the median
value of background as the expression value.
2.7. Microarray analysis on Agilent’s microarray
Microarray analyses were performed as two-colour
hybridizations as described previously.
11 Total RNAs
obtained from PBMCs were independently reverse
transcribed using oligo-dT primers containing the T7
RNA polymerase promoter sequence to generate
cDNAs, which were then subjected to in vitro tran-
scription using T7 RNA polymerase to label the
cRNAs with Cy3-CTP or Cy5-CTP (Amersham
Pharmacia Biotech, Piscataway, NJ, USA) using a
Fluorescent Linear Ampliﬁcation Kit (Agilent
Technologies Inc.). Puriﬁed Cy5-labelled cRNAs
(825 ng) from TA patients were then mixed with an
equal amount of reverse-colour Cy3-labelled cRNAs
from HV pools. Hybridizations, washing, scanning
and gene analysis with Agilent’s Whole Human
Genome Microarray 4   44K G4112F were con-
ducted according to the manufacturer’s protocol
(Agilent Technologies Inc.). Agilent Feature
Extraction software (v. 9.5.1) was used to assess spot
quality and extract feature intensity statistics. The
Subio Platform and the Subio Basic Plug-in (v1.6;
Subio Inc.) were then used to calculate the log ratio
of rProcessedSignal over gProcessedSignal (HV pools).
The details of the microarray data have been depos-
ited in the GEO (www.ncbi.nlm.nih.gov/geo) database
(accession number GSE18245). GenopalTM
and Agilent’s Whole Human Genome Microarray 4  
44K data reported in this paper have been also depos-
ited as superSeries GSE18316.
2.8. Expression proﬁling using quantitative reverse
transcription–polymerase chain reaction and
nCounterTM analyses
Assay-on-Demand TaqMan probes with relevant
primers were used for quantitative reverse transcrip-
tion–polymerase chain reaction (qPCR) analysis
using the ABI PRISM 7900 according to the manufac-
turer’s instructions (PE Applied Biosystems). Total RNA
(500 ng) obtained using the PAXgene Blood RNA Kit
was reverse transcribed with the High Capacity
cDNA Archive Kit (ABI). PCR consisted of an initial
denaturation (958C, 10 min) followed by 40 cycles
of denaturation (958C, 15 s) and annealing/extension
(608C, 1 min). A standard curve was generated from
the ampliﬁcation data for each primer using a dilution
series of PBMC RNA as the template. Fold-change
values were normalized to GAPDH expression levels
using the standard curve method according to the
manufacturer’s protocol. Measurements performed
using nCounterTM were conducted by NanoString
Technologies Inc. (Seattle, WA, USA).
3. Results
3.1. Basic design of the GenopalTM hollow ﬁbre array
To provide a useful, focused microarray system for
RNA diagnostics, we developed a novel platform
termed GenopalTM, which is comprise a hollow ﬁbre
array (Fig. 1). Different from typical glass slide DNA
microarrays, which harbour two-dimensionally cap-
tured oligonucleotide probes attached to a solid
surface, such as glass, GenopalTM consists of hollow
gel-ﬁlled ﬁbres in which oligonucleotides are uniquely
embedded in a three-dimensionally arranged manner
(Fig. 1A). The gel, which consists of copolymers con-
taining 25 mol % vinyl groups (Fig. 1B), are ﬁrmly
adhered to the inner walls of the hollow ﬁbres via
the introduction of comb polymers (Fig. 1C).
Moreover, thin slices obtained by bundling these
hollow ﬁbres and then slicing the bundle exhibited
sufﬁcient adhesion between the gel and the inner
walls of the hollow ﬁbres (Fig. 1D). A full description
of this platform is available online at http://www.
mrc.co.jp/genome/e/index.html.
GenopalTM offers a number of advantages in terms
of its low-cost, ease of storage, speed and conven-
ience compared with other microarray devices.
First, it generates hybridization signals that are suit-
able for high-precision analysis. The oligonucleotides
embedded in GenopalTM are maintained in wet con-
ditions throughout all steps of the experiment, even
during scanning, thereby allowing for rapid and easy
372 GenopalTM for Focused Microarray [Vol. 17,microarray assay. Second, it produces a large number
of microarrays with comparable quality, because the
hollow ﬁbres bundled into a single resin block are
sliced perpendicular to the longitudinal direction of
the ﬁbres; this property is particularly advantageous
for mass production at low cost when commercia-
lized as a clinical tool for RNA diagnostics, reducing
the cost down to nearly 10% of the conventional
microarrays. Third, it is durable, robust and portable,
as the sliced and packaged GenopalTM microarrays
are maintained under wet conditions. The comb
polymer, in particular, prevents the gel from detach-
ing from the inner walls at the time of slicing or
during procedures such as hybridization and
washing.
3.2. Preparation and testing of an infectant array
To examine the quality of the GenopalTM platform,
a focused DNA microarray termed the ‘infectant
array’ was designed based on 40 genes (probes)
from infectious bacteria and viruses. To design the
microarray probes, oligonucleotides 60 nts in length
were selected from the genome sequence of each
infectant, taking into consideration the melting
temperature, GC content, speciﬁcity and secondary
structure (Supplementary Table S1). The probes
were then chemically synthesized and integrated
into four independent sections of the GenopalTM
gel to test reproducibility of the assay
(Supplementary Fig. S1A). Henceforth, we will refer
to each 60 nt oligonucleotide as an iGp and each
GenopalTM array with these probes as an iGp array.
In parallel, antisense DNA (60 nts) was synthesized
for use as target DNA corresponding to each iGp
and labelled with a ﬂuorescent dye (Cy5) for efﬁcient
detection when hybridized with the infectant array
(Fig. 2A).
The hybridized signals were observed with high sen-
sitivity; even signals that were very weak after 1 s of
scanning became strong enough for analytical pur-
poses at 4 s, and these signals were saturated at 40 s
of scanning (Supplementary Fig. S1A). Four arrays,
composed of four independent sections, were
scanned four times each. In total, 64 measured
values for each probe were analysed (Fig. 2A and
Supplementary Fig. S1A). The overall CV of signal
intensities was very low (10.6% on average), indicat-
ing that the iGp array is a highly reproducible plat-
form comparable with other existing microarray
systems (Fig. 2B). Thus, the sources of variance were
analysed in detail (Fig. 2C) and the largest source
was between arrays (44.7%), as expected. The
second largest source was between sections (38.1%),
whereas variations between scans were slight
(17.3%). Taken together, these results indicate that
GenopalTM is a reliable platform for focused microar-
ray that produces reproducible results from synthetic
RNA samples.
Figure 2. iGp array set-up and data analysis. (A) Experimental
design for the use of the iGp array. Each iGp array harboured
four identical sets of 40 iGps that contained oligonucleotides
(60 nt) corresponding to various infectious bacteria and
viruses (Supplementary Table S1). Cy5-labelled antisense DNA
(60 nt) was used as a target sample that emitted ﬂuorescent
signals when hybridized with the iGps. (B) Scatter plot of
averaged signal intensities (horizontal) versus the CV of overall
variation (vertical). Four replicate samples were independently
prepared for hybridization to four iGp arrays. Each array was
scanned four times to obtain 64 measured values for each
probe in total. The average signal intensities and CVs were
calculated from these 64 values. For each 40 iGps (black
diamonds), the CV of the overall 64 average signal intensities
(%) was plotted against the original mean value of the
calculated average signal intensities. The 75th, 50th and 25th
percentile of the CVs (10.1, 11.6 and 11.9%) on the vertical
axis and the 75th, 50th and 25th percentile of the average
signal intensity (205 032.6, 191 424.1 and 185 480.5
arbitrary units) on the horizontal axis were calculated. (C)
Quantiﬁcation of the sources of variation in the replicated iGp
array. Sources of variance between arrays, between scans and
between sections, composed of array 1 to array 4, 1st scan to
4th scan, and section 1 to section 4, were calculated to be
44.7+17.00, 17.3+4.57 and 38.1+16.44% as the percent
overall variance, respectively.
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terms of speed, it was determined whether the
hybridization time, which is the most tedious step in
any DNA array, could be shortened. Thus, the span
of hybridization time was varied from 0.5 h to over-
night and compared with the resulting signal intensi-
ties (Supplementary Fig. S1B). We found that a 120-s
scan after hybridization for only 0.5 h yielded signals
that were sufﬁciently strong for signal proﬁling, even
though the signal was much reduced compared with
that of overnight hybridization (Supplementary Fig.
S1C). This result further supported the commercial
usefulness of GenopalTM.
3.3. Preparation and testing of an autoimmunity array
To evaluate the clinical applicability of GenopalTM,
we designed an ‘autoimmunity array’ based on
genes related to autoimmune diseases. For this
purpose, we selected 133 autoimmunity-related
genes that were previously identiﬁed as being up- or
down-regulated in PBMCs from patients with various
autoimmune diseases (Fig. 3A and Supplementary
Table S2), such as systemic lupus erythematosus
(SLE),
11 idiopathic thrombocytopenic purpura
(ITP),
11 rheumatoid arthritis (RA)
12 and/or vasculi-
tis.
13 In addition, 12 genes from the group of
PBMC-speciﬁc genes termed PREP (predominantly
expressed in PBMC) genes, which are highly expressed
in normal PBMCs but not in normal human ﬁbro-
blasts,
14 and 68 immunity-related genes known to
be involved in immune regulation were also used.
Genes for a-tubulin, b-tubulin and GAPDH were
used as control probes, but not as normalization
probes (Fig. 3A). In total, 216 probes were selected,
and 65 nt-long oligonucleotides were designed and
synthesized from the mRNA sequence of each gene.
These probes were termed aGp (Supplementary
Table S2: aGp #1–216), and the GenopalTM array
performed with these probes was called an aGp array.
Reference cRNA for ﬂuorescence (Cy5) labelling
was ampliﬁed using a total mRNA pool extracted
from 16 HV pools, which was used for hybridization
to the aGp array. Each hybridized aGp array was
scanned four times to estimate the variability of the
data. The average intensities of 54 of the 216
probes were greater than 50 arbitrary units (au),
and the CVs of these probes were very small
(median ¼ 4.8%); this is surprising considering the
high mRNA complexity of clinical samples. In contrast,
the CVs of the rest of probes were larger (median was
14.7%), as expected (Fig. 3B). These results indicate
that the aGp arrays also yielded reliable data,
although aGp arrays that were hybridized with clinical
mRNA samples showed lower intensities and larger
CVs than iGp arrays that were hybridized with syn-
thetic antisense DNAs.
3.4. Application of the autoimmunity array to clinical
samples
Next, an aGp array was applied to patient samples.
Fluorescently labelled cRNAs were prepared using
Figure 3. Probe design and execution of aGp arrays. (A) Distribution
of the probe groups (autoimmunity-related genes, immunity-
related genes, PREP genes and control genes) installed into the
aGp array. Each group is indicated by purple, green, red or blue
sections, respectively. Among the autoimmunity-related genes,
the numbers of up- or down-regulated genes in autoimmune
diseases are shown in parenthesis (see the leftmost column of
Supplementary Table S2 for details). The probe set of the aGp
array is comprise one-third of experimental probes (data not
shown) and two-thirds of genes associated with immunity. (B)
Scatter plot of average signal intensities (horizontal) and CV
(vertical) of the HV pool measured by the aGp array. RNA was
extracted from the PBMCs of the HV pool and hybridized onto
the aGp array. For 216 aGps on the aGp arrays, the CVs of the
average signal intensities measured four times were plotted
against the mean calculated average signal intensities. The 216
aGps are represented by grey diamonds. The average, 75th,
50th and 25th percentiles of the CVs (31.3, 22.5, 8.2 and
4.4%) on the vertical axis and the average, 75th, 50th and
25th percentiles of the average signal intensity (288.7, 49.3,
11.3 and 5.3) on the horizontal axis were calculated.
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rare autoimmune disease of the large arteries, and
used as target samples. These patients (TA1–13)
were under medical care (being treated with anti-
inﬂammatory drugs such as steroids) and were clini-
cally inactive (see Supplementary Table S3 for the
patients’ morbid states). The 13 TA cRNA samples
were hybridized to 13 aGp arrays to generate 13 bio-
logical replicates. Additionally, the TA aGp arrays were
also tested with other autoimmune diseases such as
Behc ¸et’s syndrome (BD), Churg–Strauss syndrome
(CSS), microscopic polyangiitis (MPA), malignant RA
(MRA), polyarteritis nodosa (PN) and Wegener’s gran-
ulomatosis (WG), as well as with normal volunteers
(Nor) as comparable target samples (Supplementary
Fig. S2) in order to determine whether the expression
proﬁles of the 13 TA patients were speciﬁc and useful
for the diagnosis of TA.
To validate the reference TA proﬁle described above
by averaging 13 TA samples, the Spearman rank corre-
lation for 216 aGp genes was calculated between
each sample and the reference TA proﬁle. Notably,
all TA samples (TA1–13) were highly correlated
(0.85+0.04) with the TA reference (black circles in
Fig. 4A). The maximum and the minimum values of
the Spearman rank correlation were computed to be
0.91 and 0.77, respectively, revealing an extremely
tight correlation between all TA samples (TA1–13).
Moreover, as shown by grey and white symbols in
the middle and the right areas of Fig. 4A, other
patient samples showed conspicuously low
Spearman’s rank correlation coefﬁcients (0.29+
0.12). This indicates that the aGp array is useful for
the diagnosis of TA even if the patient’s morbid state
is inactive.
Next, 34 genes were isolated that showed at least a
2-fold up-regulation and 25 genes that showed at
least a 2-fold down-regulation in at least 7 of 13 TA
patients (Supplementary Table S4). We also found
that the expression proﬁles of 59 characteristic
genes represented by line graphs in 13 TA, 17 BD, 4
CSS and 3 MPA patients distinguished TA from other
autoimmune diseases. The black lines signifying
genes that were 2-fold up- or down-regulated in at
least 7 of the 13 TA patients randomly ﬂuctuated in
other patients (Fig. 4B). Because we did not normalize
the aGp array data, systematic shifts in log-ratio distri-
butions in proportion to the signal intensities were
observed in the scatter plot (Fig. 4C). Nonetheless,
Figure 4. Expression proﬁling with the aGp array. (A) Comparison of
the Spearman rank correlation (vertical) between various
autoimmune diseases and normal individuals. Black circles, TA;
white squares, Nor (normal); black crosses, BD; white
diamonds, CSS; grey circles, MPA; a grey bar, MRA; a white
circle, PN; a grey square, WG. The number of tested individuals
is indicated in parentheses. Plots are grouped into eight
autoimmune disease groups and a HV (Nor) group. All of the
13 TA patients (black circles) are highly correlated by the
Spearman rank correlation (r ¼ 0.85+0.04), whereas other
autoimmune disease groups and the HV pool group showed
distinctively lower correlation coefﬁcients (Nor, 0.24; BD, 0.23;
CSS, 0.43; MPA, 0.26; MRA, 0.38; PN, 0.37; WG, 0.31). (B) Line
graphs showing the expression proﬁles of 59 characteristic
genes in patients with TA,
13 BD, CSS
4 and MPA.
3 The number
of examined patients is indicated in parentheses. The colour
bar at the right side of the panel indicates the log2 ratio for
each patient versus the HV pool sample. Line colours with
intensity gradients indicate the mean values of relative
expression: blue (down-regulation) corresponds to a log2 ratio
22, and crimson (up-regulation) corresponds to a log2 ratio 2
when each patient and HV pool are compared. Black lines
signify genes that are 2-fold up- or down-regulated in at least
7 of the 13 TA patients compared to the HV pool sample (see
Supplementary Table S4 for details). (C) Scatter plot of the
average signal intensities (in log scale) of the 13 TA patients
versus the HV pool sample, plotted along the vertical and
horizontal axes, respectively. Black spots indicate the 59
characteristic genes described above. The colour bar indicates
the signal intensity of the 13 TA patients versus the HV pool
sample. Circle colours with intensity gradients indicate the
mean value of the expression level: blue (down-regulation)
corresponds to a signal intensity of 10, and crimson (up-
regulation) corresponds to a signal intensity of 250 when the
average value of the 13 TA patients and the HV pool are
compared. Black circles signify genes that are 2-fold up- or
down-regulated in at least 7 of the 13 TA patients compared
with the HV pool sample (see Supplementary Table S4 for
details).
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of correlation across the 216 genes. Namely, up- or
down-regulated genes (black circles in Fig. 4C) loca-
lized outside the diagonal bundles of dots (purple
and crimson circles in Fig. 4C) over a wide range of
intensities. In contrast, these 59 genes showed no
obvious correlation patterns in other patient
samples (data not shown).
Notably, the aGp array has additional practical
advantages for clinical use because the obtained
data were found to be very stable after scanning,
even without sealing or other direct countermeasures
against exposure to ozone (Supplementary Fig. S3).
Moreover, the background level of the data after
19–27 days were largely reduced compared with
1 day data, which conﬁrmed the reliability of the
data even with low signal intensity. Taken together,
these results indicate that aGp arrays are clinically
useful because they can clearly distinguish TA
patient proﬁles from other patients by the
Spearman rank correlation using all 216 probes.
3.5. Comparison between aGp array, Agilent’s
microarray and qPCR
Next, the performance of aGp arrays was compared
with other tools to examine the variation of the
expression patterns of the genes in the 13 TA
patient samples. First, all TA samples (TA1–13) were
applied to Agilent’s Whole Human Genome
Microarray (4   44K). DEFA3, interleukin (IL)-4 and
IL-10 were selected for further analysis because they
are known to be highly associated with various auto-
immune diseases.
14 When the expression proﬁles of
each gene from aGp array, Agilent’s microarray and
qPCR are compared, represented by green, purple
and blue lines, respectively, it is apparent that DEFA3
achieved almost complete correlation among the
three measurement systems (Fig. 5A). This correlation
is surprising considering the distinct sequences of the
probes used in each measurement and further con-
ﬁrmed the reliability of the data obtained by aGp
arrays. In contrast, IL-4 and IL-10 showed distinct
expression patterns depending on the system
(Fig. 5Bi and ii).
Notably, IL-4 and IL-10 were expressed at remark-
ably low levels compared with DEFA3 (indicated by
arrows in Fig. 6A). The scatter plot of log signal inten-
sities from the HV pool (horizontal) and patient TA8
(vertical) show that the signal intensities of IL-4 and
IL-10 are considerably lower than that of DEFA3. In
addition, the correlation coefﬁcients of DEFA3 for
the averaged signal intensities of the aGp array and
Agilent’s microarray against qPCR normalized to
GAPDH (0.93 and 0.96) are signiﬁcantly higher
than those of IL-4 (20.52 and 0.52) and IL-10
(0.12 and 20.06), respectively (Fig. 6B).
3.6. Comparison with nCounterTM
To investigate whether aGp or Agilent provided
more reliable results, we employed nCounterTM by
NanoString
15 and measured the expression levels of
25 relevant genes (aGps) using one patient sample
(TA8). The raw data revealed that the expression
levels of IL-4 and IL-10 in this patient were very low
Figure 5. Expression proﬁles of DEFA3 (A), IL-4 (Bi) and IL-10 (Bii)
in the 13 TA patients. The vertical axis indicates the log2 ratio
measured by qPCR–GAPDH (blue), aGp array (green) and
Agilent’s microarray (purple). The horizontal axis indicates the
patient number. (A) The comparison of the values of peaks
and valleys for DEFA3 revealed that these three methods
yielded very similar expression proﬁles. (Bi and ii) The
expression proﬁles of the IL-4 and IL-10 genes for the 13 TA
patients were different between qPCR–GAPDH (blue), aGp
array (green) and Agilent’s microarray (purple).
376 GenopalTM for Focused Microarray [Vol. 17,and that 10 of the 25 genes were up-regulated more
than 2-fold compared with the HV sample (green
arrows in Supplementary Fig. S4). Comparison of the
relative induction rates between aGp, Agilent and
nCounterTM revealed that 12 of the 25 genes
(yellow arrows in Fig. 7) had similar results in all
three methods, whereas nCounterTM favoured aGp
arrays (turquoise arrows) or Agilent (pink arrows)
for three and the six genes, respectively. The other
four genes (purple arrows) showed distinct results
among these three methods. As both nCounterTM
and qPCR favoured aGp arrays for IL-10 and Agilent
for IL-4 (Supplementary Fig. S5), it is difﬁcult to deter-
mine at present which microarray provided more
reliable results. Taken together, these results led us
to conclude that aGp arrays provide reliable data at
a level similar to Agilent’s microarray, particularly
when the expression levels of the target gene are
not very low.
4. Discussion
In the present study, we describe a novel platform
termed GenopalTM that is ideal for the preparation
of focused microarray (Fig. 1). We ﬁrst designed the
iGp array, examined its performance using Cy5-
labelled synthetic oligonucleotides as hybridization
probes (Fig. 2A) and determined that it yielded
highly reproducible data (Fig. 2B; CV was 10.6% on
average). We also prepared the aGp array and tested
their clinical applicability using RNA samples from a
small volume of PBMCs obtained from TA patients
(Fig. 3B and Supplementary Table S3). We do not
exclude the usefulness of other genes that were not
installed into the aGp array. Nonetheless, we showed
that the aGp array is able to distinguish TA patient
proﬁles from HVs and patients with other auto-
immune diseases based on the Spearman rank corre-
lation using all 216 probes (Fig. 4). Notably, this data-
processing protocol is quite simple and extensible; all
that is needed is to calculate the ratio of the
Spearman rank correlation for the patients’ and HV
pool samples. This protocol is useful only for analysis
of small number of genes and cannot be applied to
conventional genome-wide microarrays, which is
another advantageous point of GenopalTM.
Comparison of the data obtained by an aGp array,
Agilent’s microarray, qPCR and nCounterTM indicated
that these methods exhibited similar expression pro-
ﬁles with regard to target genes with high signal
intensities (Figs 5–7).
Figure 6. The aGp array provides sufﬁcient sensitivity for diagnostic
application. (A) A scatter plot of the log of signal intensity of the
HV pool versus patient TA8 is plotted along the horizontal and
vertical axes, respectively. DEFA3, IL-4 and IL-10 genes are
indicated by orange arrows. The attached colour bar indicates
a relative intensity scale. (B) The correlation coefﬁcients of the
GenopalTM autoimmunity array and Agilent’s microarray
against qPCR are shown. The correlation coefﬁcient of DEFA3
for both GenopalTM and Agilent’s arrays was high. On the
other hand, because the signal intensities of IL-4 and IL-10
were within two orders of magnitude, as shown in the
columns on the right, the correlation coefﬁcient of IL-4 or
IL-10 is lower than DEFA3.
Figure 7. Comparison of the mRNA expression levels (y-axis) of 25
selected genes (x-axis) in PBMCs of patient TA8 using
nCounterTM (blue bars), aGp array (GenopalTM; red bars) or
Agilent’s microarray (green bars). Yellow arrows indicate genes
that had similar expression levels in the three methods.
Turquoise or pink arrows indicate the genes used by
nCounterTM to favour aGp or Agilent in terms of their
expression levels. Purple arrows indicate the genes that
exhibited different expression levels among the three methods.
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genes that were up- or down-regulated in almost all
TA patients tested (Supplementary Table S4). Among
the up-regulated genes, S100A8, S100A9 and
S10012 are inﬂammation-related genes. This is not
unexpected because TA is an autoimmune disease
that involves enhanced inﬂammation of the aorta.
The up-regulation of amphiregulin (AREG), which is
a member of the epidermal growth factor family,
may be related to the ventricular hypertrophy often
observed in TA patients. Alternatively, it may be
involved in the maintenance of inﬂammatory situ-
ations by inducing the proliferation of regulatory
cells in these phenomena. Enhanced expression of
IL-1 receptor, type II (IL-1R2), a decoy receptor that
traps pro-inﬂammatory IL-1b and does not initiate
subsequent signalling events, may be due to a nega-
tive feedback response to the hyperactive inﬂam-
mation in the aorta of TA patients (which results
partially from steroid therapy). Defensins, which
include DEFA3, are a family of microbicidal and cyto-
toxic peptides that are abundant in the granules of
neutrophils and are thought to be involved in host
Defence, which suggest the involvement of infection
in the pathogenesis of TA. In contrast, interferon
gamma (IFN-G) and interferon-induced genes
(G1P2, IFI44, IFIT1, IFIT2 and IFI27) were down-regu-
lated in many TA patients, which distinguish TA from
SLE and ITP, as these genes are up-regulated in the
latter autoimmune diseases. As there is no reliable
diagnostic tool for TA at present, these genes may
also be useful as diagnostic markers of the disease
when used in combination with the Spearman rank
correlation method described above.
One of the practical applications of iGp and aGp
arrays would be their use in the diagnosis of patients
afﬂicted with fever of unknown origin (FUO). Our pro-
posal is presented schematically in Supplementary
Fig. S6. Namely, a 2-ml blood sample may be col-
lected for every new FUO patient using PAXgene
Blood RNA Kits of Quiagen, total RNA prepared,
labelled with Cy5 and applied to an aGp array. As
the aGp array harbours genes that are either up- or
down-regulated in the PBMCs of several autoimmune
diseases, such as SLE,
11 ITP,
11 RA
12 and/or vasculi-
tis,
13 we expect to observe positive signals if the
patient’s FUO is related to any of these autoimmune
diseases. In this case, the FUO patient may be directly
referred to an autoimmune disease specialist to
receive appropriate care. If the screen yielded negative
results, other sample sources, such as phlegm and/or
excrement, depending on the dubious infectants, may
be collected for RNA preparation and screening using
the iGp array. If a positive signal is detected, the
patients could then be treated appropriately at the
bedside. Recent reports indicate that GenopalTM is
useful not only for cRNA but also for miRNA
samples.
16–20
Taken together, we conclude that GenopalTM is an
advantageous platform for focused microarrays with
regard to its low cost, reliability, ease of storage,
speed and suitability for large-scale production. The
data-processing protocol we developed here might
be quite useful for the diseases that lack diagnostic
tools using conventional clinical methods.
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